OR WAIT null SECS
ORACLE INDUSTRY CONNECT, WASHINGTON DC-March 26, 2015-Contract research organizations (CROs) are constantly looking for ways to improve project oversight and reduce costs while adding value and simplifying data exchange-especially in complex clinical trials involving multiple CRO partners. Pharmaceutical Product Development, LLC (PPD), a leading global CRO, looked to Oracle Health Sciences Cloud for a solution. PPD is the first CRO to migrate trials from an onsite installation of Oracle’s Siebel Clinical Trial Management System to Siebel Clinical Trial Management System Cloud Service-creating a highly available, centralized-trial database that lowers costs, simplifies the management and improves the accuracy of multi-CRO clinical trial data, and accelerates studies. Ovum recognized Siebel Clinical Trial Management System as a market leader in its “Ovum Decision Matrix: Selecting a CTMS Solution, 2013–14” report.
“Oracle Siebel Clinical Trial Management System Cloud Service dramatically simplifies how we manage study data and communicate with clients, especially in studies involving multiple CROs,” said Andrew Masters, vice president of enterprise information management, PPD. “Clients can now access study data through Oracle’s Siebel cloud Service, so we no longer need to send data back and forth to them, saving us time, reducing the cost of studies and creating better results for our clients.”
Using Siebel Clinical Trial Management System Cloud Service with a standardized clinical trial management system (CTMS) configuration, PPD migrated data from 124 studies to the Oracle Health Sciences Cloud in just six weeks, achieving rapid time to value. In addition, the organization is reducing the in-house resources needed to support these trials by using the cloud to simplify the exchange of data for multi-CRO studies. With the highly available and secure monitoring cloud, PPD and trial sponsors gain actionable insight into studies to accelerate clinical development while reducing trial costs and risk.
“Oracle’s Siebel Clinical Trial Management System Cloud Service delivers comprehensive clinical trial management with all the performance, scalability, and cost benefits of Oracle Health Sciences Cloud,” said Steve Rosenberg, senior vice president and general manager, Oracle Health Sciences. “The success of PPD, one of the world’s largest CROs, in rapidly migrating data from an on-premises environment to Siebel Clinical Trial Management System Cloud Service demonstrates the flexibility of the solution and its ability to simplify data exchange, ultimately leading to more-efficient clinical trial management.”
Siebel Clinical Trial Management System combines standardized, comprehensive clinical trial capabilities, integrated analytics tools, and unsurpassed data security with a cloud service that lets organizations effectively and economically manage clinical trial activities and improve CRO and sponsor relationships from early to late-stage clinical trials.
Validating Oracle’s industry leadership, Ovum, a leading IT research and analyst group, has positioned Siebel Clinical Trial Management System as a market leader in its “Ovum Decision Matrix: Selecting a CTMS Solution, 2013–14” report based on “its market share, breadth of offering, and long-term vision.” This report compares products of the top five CTMS vendors to help life sciences organizations better understand the CTMS vendor landscape. Siebel Clinical Trial Management System led the technology assessment category, scoring highest in breadth of offering, usability, development, and reporting.
“Ovum designates a market leader as having established a commanding market position with a product that is widely accepted as best of breed and worthy of a place on most technology selection shortlists,” said Andrew Brosnan, senior analyst, Ovum Health Sciences team. “Oracle’s support for mobile CRAs, risk-based monitoring platform, and integration with its Oracle Health Sciences Clinical Development Analytics product differentiates its offering from the rest of the market.”